NCATS and NHGRI Seeking CRADA Partners for Pre-Clinical Development of Small Molecule Therapeutics
CRADA collaboration opportunities are being offered by the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) to facilitate the development of small molecule compounds early in the development cycle. Both collaborations will focus on the final stages of lead optimization, evaluation, and preclinical development of these compounds. These solicitations will close on March 8, 2013.
NCATS is seeking CRADA partners for development of small molecule agonists of the mammalian relaxin hormone receptor for the treatment of heart failure and fibrosis. Further details relating to the underlying technology, project scope, and proposal guidelines can be found in the Federal Register notice for this opportunity at https://federalregister.gov/a/2013-02611.
A second CRADA opportunity is available for development of a novel selective series of non-inhibitory chaperones of glucocerebrosidase (GCase) developed jointly by NCATS and NHGRI for the treatment of Gaucher disease, Parkinson’s disease, and other diseases. Further details relating to the underlying technology, project scope, and proposal guidelines can be found in the Federal Register notice for this opportunity at https://federalregister.gov/a/2013-02609.